Melanotan I vs Melanotan II: Receptor Selectivity Is the Difference

The short answer

Melanotan I is selective for the MC1R melanocortin receptor. Melanotan II is a non-selective melanocortin agonist - it engages MC1R but also other melanocortin receptors including MC3R and MC4R. Melanotan II is not a newer or improved Melanotan I; it is a structurally different, shorter cyclic analog with a broader receptor profile.

Why selectivity matters in research

Melanocortin receptors are a family, and the different members are expressed in different tissues and coupled to different downstream pathways. A compound selective for one receptor produces a narrower set of observable effects in a study; a non-selective agonist engages several pathways at once, which makes attributing an observation to a specific receptor harder.

That is a methodological point rather than a safety ranking: for a research design aiming to isolate MC1R signalling, a selective compound and a non-selective one are not interchangeable tools.

The PT-141 connection

PT-141 is a derivative of Melanotan II and appears in a separate research literature again, focused on different melanocortin receptor activity. Its existence illustrates the point: within one compound family, receptor selectivity is the axis along which the research separates.

Evidence and handling

Both are supplied as lyophilized powders and reconstituted with bacteriostatic water, stored cold and dark. Published human data for both is limited relative to their visibility, and much of the available literature is mechanistic. Non-selective receptor engagement means a broader range of observed effects in study models, which is a reason to read the Melanotan II literature carefully rather than a reason to assume equivalence with Melanotan I.